Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
Status:
Active, not recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine safety and tolerability of the combination of
talimogene laherparepvec in combination with dabrafenib and trametinib in BRAF mutated
advanced melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
West Cancer Center
Collaborators:
Amgen University of Tennessee Health Science Center